A double-blind short-term presurgical study to assess the molecular predictors of the antiproliferative effects of lapatinib in women with primary breast cancer
Latest Information Update: 26 Jun 2023
Price :
$35 *
At a glance
- Drugs Lapatinib (Primary)
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms MAPLE
- 04 Apr 2012 Results presented at the 103rd Annual Meeting of the American Association for Cancer Research.
- 18 Aug 2011 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network.
- 31 Jul 2011 Planned end date changed from 31 Dec 2010 to 31 May 2011 as reported by United Kingdom Clinical Research Network.